Skin News and Research

RSS

VCU researchers discover mechanism that regulates gene expression and growth in melanoma cells

Virginia Commonwealth University researchers have discovered a mechanism by which an enzyme regulates gene expression and growth in melanoma cells, a finding that could someday lead to more effective drugs to attack cancers and make them more treatable.

18 Jun 2010

Transdel, JMSR enter into licensing agreement

Transdel Pharmaceuticals, Inc. and Jan Marini Skin Research, Inc. have entered into a licensing agreement providing JMSR with the exclusive U.S. rights to Transdel's transdermal delivery technology for use in an anti-cellulite cosmeceutical product for the dermatological market.

18 Jun 2010

FDA approves Jevtana to treat men with prostate cancer

The U.S. Food and Drug Administration today approved Jevtana (cabazitaxel), a chemotherapy drug used in combination with the steroid prednisone to treat men with prostate cancer. Jevtana is the first treatment for advanced, hormone-refractory, prostate cancer that has worsened during or after treatment with docetaxel, a commonly used drug for advanced prostate cancer.

18 Jun 2010

Nineteen facilities named Centers of Excellence in APBI for use of SAVI applicator

Nineteen facilities in the Mid-Atlantic region have been named Centers of Excellence in accelerated partial breast irradiation for their use of the SAVI applicator, an advanced therapy for breast cancer as part of breast conservation therapy. The SAVI applicator can provide important advantages for women with early-stage breast cancer.

17 Jun 2010

One in three people with psoriasis do not receive proper treatment due to health insurance issues: Survey

Results from a new survey reveal that one in three people with psoriasis do not receive proper treatment for their disease due to health insurance issues—and many won't be helped by the new health care reform law.

17 Jun 2010

LWW sponsors symposium on wound care

The 25th Anniversary Clinical Symposium on Advances in Skin & Wound Care: The Conference for Prevention and Healing will be held September 30-October 3, 2010, at the Gaylord Palms Hotel and Convention Center in Kissimee, FL. The symposium is sponsored by Lippincott Williams & Wilkins (LWW), part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

17 Jun 2010

CINJ researchers combine series of vaccination injections to treat prostate cancer

Looking to harness the body's own immune system to target prostate cancer that has spread to the bones (metastatic) and is unresponsive to standard treatment, investigators at The Cancer Institute of New Jersey have just launched a clinical trial focusing on a combination of vaccine and radiation drug therapy.

17 Jun 2010

Trius Therapeutics reaches agreement with FDA under SPA for Phase 3 study of torezolid phosphate for ABSSSI

Trius Therapeutics, Inc. announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study for the oral dosage form of torezolid phosphate for treatment of acute bacterial skin and skin structure infections (ABSSSI).

16 Jun 2010

Identification of key player in signaling pathway offers hope for new targeted melanoma therapies

Identification of a key player in a signaling pathway involved in the development of melanoma - the deadliest form of skin cancer - may offer hope for new targeted melanoma therapies.

16 Jun 2010

Microneedle skin patches as effective as hypodermic needles for flu vaccination

Flu vaccine delivered through skin patches containing microneedles has proven at least as effective at preventing influenza in mice as intramuscular, hypodermic flu immunization.

16 Jun 2010

Synthetic sutures less painful than natural "catgut" sutures after vaginal birth

Synthetic sutures appear to cause less pain than natural "catgut" sutures in women who receive stitches after a vaginal birth, according to a new review of studies.

16 Jun 2010

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced results from a pre-clinical study showing that calcipotriene 0.005% and betamethasone dipropionate 0.064%, when formulated with NexACT®, results in a topical treatment which shows bioequivalecy in efficacy to Talconex®, one of the leading topical treatments marketed for patients with mild to moderate psoriasis.

16 Jun 2010

Study validates Grm1 protein as target for melanoma treatment

Research by investigators at The Cancer Institute of New Jersey (CINJ) is showing new promise in the treatment of melanoma, the most serious of skin cancers. The findings, published in the May 27, 2010, online edition of the Journal of Investigative Dermatology further validate the team's clinical and pre-clinical findings that blocking the signaling normally activated by a receptor called Grm1 results in decreased cell growth and decreased migration of melanoma cells, confirming that Grm1 is a potential target for the treatment of melanoma.

16 Jun 2010

Combination of BRAF-targeted therapy and immunotherapy shows promise for treatment of melanoma

Combined targeted therapy against the BRAF/MAPK pathway with immunotherapy shows promise as a new therapeutic approach for the treatment of melanoma, according to results of a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

16 Jun 2010

ISB, GIND collaborate on whole-genome sequencing to identify drug targets for Huntington's Disease

The Institute for Systems Biology (ISB) of Seattle, WA, is collaborating with the Gladstone Institute of Neurological Disease (GIND) and its Taube-Koret Center for Huntington's Disease Research to use whole-genome sequencing to identify genes and novel drug targets related to the onset and progression of Huntington's disease (HD). The research team, led by GIND associate director and senior investigator Steven Finkbeiner, MD, PhD, will also use induced pluripotent stem (iPS) cells from patients with HD to screen for drugs that might delay, prevent, or even reverse this devastating condition.

16 Jun 2010

Topical NSAIDs are safe and effective for acute pain: Researchers

Gels, creams and sprays containing painkillers such as ibuprofen, diclofenac, ketoprofen, and piroxicam are safe and effective treatments for local pain, according to Cochrane Researchers. A new systematic review they have conducted shows that topical non-steroidal anti-inflammatory drugs are more effective than placebos for treating short-term pain and have few side effects.

16 Jun 2010

Vitamin D may help reduce incidence, severity of viral respiratory tract infections: Study

Vitamin D may help reduce the incidence and severity of viral respiratory tract infections including influenza, according to a new study conducted by investigators at Greenwich Hospital and Yale University School of Medicine.

16 Jun 2010

Sanofi-aventis signs definitive agreement to acquire assets of Canderm

Sanofi-aventis announced today that it has entered into a definitive agreement under which an affiliate of sanofi-aventis Canada Inc. is to acquire the assets of Canderm Pharma Inc., a privately-held leading Canadian skin care company. This agreement is consistent with the sanofi-aventis Group's global strategy to expand its consumer health care growth platform and follows on the heels of the Group's acquisition of the North American CHC company Chattem Inc. in March 2010.

16 Jun 2010

Tips for correct application of sunscreen

You've gotten the message about the importance of sun protection, you're stocked up on sunscreen that's at least 15 SPF, and you're diligent about putting it on before you head outside. Once you've gotten this far, there's no reason to risk sunburns by applying it incorrectly. But, all too often, that's exactly what happens, says a Saint Louis University dermatologist.

15 Jun 2010

First patient treated in multicentre Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine for melanoma

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announces the enrolment and treatment of the first patient in its multicentre Phase I clinical trial of SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma. The trial will evaluate the safety and tolerability of SCIB1 in patients with late stage melanoma.

15 Jun 2010

Skin News and Research

VCU researchers discover mechanism that regulates gene expression and growth in melanoma cells

Transdel, JMSR enter into licensing agreement

FDA approves Jevtana to treat men with prostate cancer

Nineteen facilities named Centers of Excellence in APBI for use of SAVI applicator

One in three people with psoriasis do not receive proper treatment due to health insurance issues: Survey

LWW sponsors symposium on wound care

CINJ researchers combine series of vaccination injections to treat prostate cancer

Trius Therapeutics reaches agreement with FDA under SPA for Phase 3 study of torezolid phosphate for ABSSSI

Identification of key player in signaling pathway offers hope for new targeted melanoma therapies

Microneedle skin patches as effective as hypodermic needles for flu vaccination

Synthetic sutures less painful than natural "catgut" sutures after vaginal birth

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

Study validates Grm1 protein as target for melanoma treatment

Combination of BRAF-targeted therapy and immunotherapy shows promise for treatment of melanoma

ISB, GIND collaborate on whole-genome sequencing to identify drug targets for Huntington's Disease

Topical NSAIDs are safe and effective for acute pain: Researchers

Vitamin D may help reduce incidence, severity of viral respiratory tract infections: Study

Sanofi-aventis signs definitive agreement to acquire assets of Canderm

Tips for correct application of sunscreen

First patient treated in multicentre Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine for melanoma

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News